TopiVert is developing novel NSKI products as potential breakthrough treatments in the fields ophthalmic (eye) and inflammatory gastrointestinal (GI) diseases.

Our NSKIs, through targeting several important kinases involved in the inflammatory cascade, synergistically inhibit key pathways involved in innate and adaptive immunity.  Their specific structural properties have been designed such that NSKIs act and are retained locally in the target tissue, with only minimal systemic absorption to reduce the propensity for use-limiting side-effects as seen with currently available treatments. NSKIs therefore have the potential to provide highly effective and safe long-term treatments in our target diseases.

Ocular inflammatory disease

Ocular inflammatory disease (OID) is a general term for inflammation affecting any part of the eye or surrounding tissue. It extends from common conditions such as dry eye syndrome, which affects an estimated 40 million people in the US alone and can often be treated with over-the-counter (OTC) medications, to rarer but potentially more serious conditions such as uveitis and retinal diseases which can be sight-threatening.

Treatments commonly include anti-inflammatory drugs such as steroids, and immunosuppressant drugs but these are not suitable for long-term use due to their adverse event profiles. Meanwhile, many patients with dry eye disease self-medicate with artificial tears bought OTC to help gain symptomatic relief but there is a pressing need for more effective, long-term therapies.

Our lead eye indication is dry eye disease (DED) - click here for more details.

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a term used to describe several diseases that involve inflammation of the GI tract. It is estimated that the two most common forms of IBD, Crohn’s disease and ulcerative colitis (UC), affect more than 4 million people worldwide. These chronic relapsing remitting diseases cause bloody diarrhoea, abdominal pain and significant reductions in quality of life.

The cause, while not fully understood, is thought to be due to an abnormal inflammatory reaction in the intestinal tract that leads to a breakdown of the intestinal wall. As a result, drug therapy is primarily with anti-inflammatory drugs, immunosuppressants, and biological therapy targeting specific components of the immune response. However, some patients fail to respond to treatment with these drugs in the short-term while these drugs are either considered not effective and or not suitable for long-term use in those that do respond initially.  As a result, a significant number of patients progress to surgery to help manage intractable disease and/or complications.

Our lead GI indication is UC - click here for more details.